GRACEcast-084_Lung-Cancer_ALK Inhibition: Science and Early Clinical Experience by Dr. Ben Solomon

4 意见
administrator
administrator
07/30/23

http://cancergrace.org/

Dr. Ben Solomon of Peter MacCallum Cancer Centre in Melbourne Australia reviews ALK Inhibition from mechanism of action to activity and side effect profile of crizotinib, newly approved for patients with ALK-positive advanced non-small cell lung cancer.

  • 类别

显示更多

0 注释 排序方式

没有找到评论

脸书评论

下一个